BVAXF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
7.49M
CSBR
Price
$7.76
Change
+$0.54 (+7.48%)
Updated
Jun 27 closing price
Capitalization
105.36M
18 days until earnings call
Interact to see
Advertisement

BVAXF vs CSBR

Header iconBVAXF vs CSBR Comparison
Open Charts BVAXF vs CSBRBanner chart's image
BioVaxys Technology
Price$0.03
Change-$0.00 (-0.00%)
Volume$515.82K
Capitalization7.49M
Champions Oncology
Price$7.76
Change+$0.54 (+7.48%)
Volume$40.47K
Capitalization105.36M
BVAXF vs CSBR Comparison Chart in %
Loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BVAXF vs. CSBR commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVAXF is a Hold and CSBR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (BVAXF: $0.03 vs. CSBR: $7.76)
Brand notoriety: BVAXF and CSBR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVAXF: 59% vs. CSBR: 115%
Market capitalization -- BVAXF: $7.49M vs. CSBR: $105.36M
BVAXF [@Biotechnology] is valued at $7.49M. CSBR’s [@Biotechnology] market capitalization is $105.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVAXF’s FA Score shows that 0 FA rating(s) are green whileCSBR’s FA Score has 1 green FA rating(s).

  • BVAXF’s FA Score: 0 green, 5 red.
  • CSBR’s FA Score: 1 green, 4 red.
According to our system of comparison, CSBR is a better buy in the long-term than BVAXF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 4 TA indicator(s) are bullish.

  • CSBR’s TA Score: 4 bullish, 6 bearish.

Price Growth

BVAXF (@Biotechnology) experienced а +5.47% price change this week, while CSBR (@Biotechnology) price change was -7.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

BVAXF is expected to report earnings on Mar 31, 2025.

CSBR is expected to report earnings on Sep 10, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSBR($105M) has a higher market cap than BVAXF($7.49M). CSBR YTD gains are higher at: -9.452 vs. BVAXF (-31.678). CSBR has higher annual earnings (EBITDA): 8.43M vs. BVAXF (-4.13M). CSBR has more cash in the bank: 3.2M vs. BVAXF (157K). BVAXF has less debt than CSBR: BVAXF (67.7K) vs CSBR (6.44M). CSBR has higher revenues than BVAXF: CSBR (58.6M) vs BVAXF (0).
BVAXFCSBRBVAXF / CSBR
Capitalization7.49M105M7%
EBITDA-4.13M8.43M-49%
Gain YTD-31.678-9.452335%
P/E RatioN/A16.93-
Revenue058.6M-
Total Cash157K3.2M5%
Total Debt67.7K6.44M1%
FUNDAMENTALS RATINGS
BVAXF vs CSBR: Fundamental Ratings
BVAXF
CSBR
OUTLOOK RATING
1..100
5135
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10010
PRICE GROWTH RATING
1..100
8944
P/E GROWTH RATING
1..100
10077
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVAXF's Valuation (39) in the null industry is somewhat better than the same rating for CSBR (83) in the Biotechnology industry. This means that BVAXF’s stock grew somewhat faster than CSBR’s over the last 12 months.

BVAXF's Profit vs Risk Rating (100) in the null industry is in the same range as CSBR (100) in the Biotechnology industry. This means that BVAXF’s stock grew similarly to CSBR’s over the last 12 months.

CSBR's SMR Rating (10) in the Biotechnology industry is significantly better than the same rating for BVAXF (100) in the null industry. This means that CSBR’s stock grew significantly faster than BVAXF’s over the last 12 months.

CSBR's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for BVAXF (89) in the null industry. This means that CSBR’s stock grew somewhat faster than BVAXF’s over the last 12 months.

CSBR's P/E Growth Rating (77) in the Biotechnology industry is in the same range as BVAXF (100) in the null industry. This means that CSBR’s stock grew similarly to BVAXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBR
RSI
ODDS (%)
Bearish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 12 days ago
73%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGFFX50.470.33
+0.66%
Sparrow Growth A
SUSSX15.270.10
+0.66%
State Street Instl US Equity Svc
TWMTX129.520.70
+0.54%
Transamerica US Growth T
GQGIX17.380.07
+0.40%
GQG Partners Emerging Markets EquityInst
JUSPX16.490.02
+0.12%
JPMorgan US Small Company R3

BVAXF and

Correlation & Price change

A.I.dvisor tells us that BVAXF and GSGTF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BVAXF and GSGTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BVAXF
1D Price
Change %
BVAXF100%
N/A
GSGTF - BVAXF
29%
Poorly correlated
N/A
THTX - BVAXF
24%
Poorly correlated
+0.43%
EDSA - BVAXF
21%
Poorly correlated
+5.03%
CSBR - BVAXF
21%
Poorly correlated
+7.48%
SQZB - BVAXF
14%
Poorly correlated
N/A
More

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and SYRE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+7.48%
SYRE - CSBR
32%
Poorly correlated
-4.99%
SCNI - CSBR
27%
Poorly correlated
-7.69%
OABI - CSBR
25%
Poorly correlated
+0.59%
CVAC - CSBR
25%
Poorly correlated
-0.37%
MREO - CSBR
24%
Poorly correlated
-5.00%
More